Company: TVRD
Filing Date: 2025-10-07
Form Type: S-1/A
Source: 0001104659-25-097519
Chunk: 358

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-10-07
Form: S-1/A
Chunk 358
---
2025, the Company evaluated all available evidence and concluded that a valuation allowance is still required against its net deferred tax assets because it is more likely than not they will not be realized in the foreseeable future.

F-46

12.Net Income (Loss) Per Share

Basic and diluted net income (loss) per share attributable to common stockholders was calculated as follows (dollar amounts in thousands):

| ​                                                                                           
 ​                                                                                           
 ​                                                                                           
 Numerator:                                                                                  | ​ 
 ​ | ​                                   
 For the Three Months Ended June 30, 
 2025                                
 ​                                   |         ​ | ​ | ​    
 2024 
 ​    |         ​ | ​ 
 ​ | ​                                 
 For the Six Months Ended June 30, 
 2025                              
 ​                                 |         ​ | ​ | ​    
 2024 
 ​    |         ​ |
|:--------------------------------------------------------------------------------------------|:--|:------------------------------------|----------:|:--|:-----|----------:|:--|:----------------------------------|----------:|:--|:-----|----------:|
| Net income (loss) for basic net income (loss) per share attributable to common stockholders | ​ | $                                   |     4,167 | ​ | $    |    -6,975 | ​ | $                                 |    -5,412 | ​ | $    |   -11,177 |
| Reversal of fair market value remeasurement gain on Convertible Notes (1)                   | ​ | ​                                   |   -12,752 | ​ | ​    |         — | ​ | ​                                 |    -7,810 | ​ | ​    |         — |
| Add back of interest expense from the Convertible Notes (1)                                 | ​ | ​                                   |        93 | ​ | ​    |         — | ​ | ​                                 |       651 | ​ | ​    |         — |
| Net loss for diluted net loss per share attributable to common stockholders                 | ​ | $                                   |    -8,492 | ​ | $    |    -6,975 | ​ | $                                 |   -12,571 | ​ | $    |   -11,177 |
| ​                                                                                           | ​ | ​                                   |         ​ | ​ | ​    |         ​ | ​ | ​                                 |         ​ | ​ | ​    |         ​ |
| Denominator:                                                                                | ​ |                                     |           | ​ |      |           | ​ |